The raise supports Perelel’s move into a full spectrum lifecycle supplement platform across hormonal health.
"This moment validates what we’ve built over the past five years: a business that proves women trust and return to brands that invest in clinical rigor and medically backed solutions."
— Victoria Thain Gioia, Co-Founder and CEO, Perelel
"Nest has demonstrated that bringing care directly into the home can help improve health outcomes and cost savings. The team's unique combination of clinical acumen and technology expertise positions them to scale this impact nationwide.”
— Tim Howe, Partner, Socium Ventures
The biotech will advance development of next generation therapeutics designed to improve outcomes for women with breast cancer.
The approval increases access to treatment for people with HER2 positive breast cancer by introducing the first biosimilar alternative to Perjeta.
"Expanding access to treatments for diseases that disproportionately impact women, including breast cancer, the most common cancer among women in the US, excluding skin cancer, is at the core of our mission"
— Jon Martin, US Commercial Lead, Biosimilars and Established Brands, Organon
The alliance aims to broaden access and support the growth of fertility services for women and families across the country.
"With Amulet increasing its investment and L Catterton joining as a partner, we are better positioned than ever to expand access to fertility care, advance clinical research and innovation"
— Richard Jennings, Chief Executive Officer of US Fertility
🔗 Read More
On 4 December, Zurich becomes a hub for women’s health innovation as Philips, Groupe Mutuel and Tech4Eva return with insights, honest conversations and a standout startup showcase. One final showcase slot remains. If you are shaping the future of women’s health, step forward.
Another powerful week for women’s health. 💪
Let us know what you're working on, or who we should feature next. Email us at info@womenshealthweek.com and put "Scoop Request" as the subject!
